## Kimberly A Morishita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3060650/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2015, 74, 1854-1860.	0.5	192
2	Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study. Arthritis and Rheumatology, 2016, 68, 2514-2526.	2.9	103
3	Musculoskeletal manifestations of mucopolysaccharidoses. Rheumatology, 2011, 50, v19-v25.	0.9	72
4	The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2016, 75, 1092-1098.	0.5	72
5	Mortality in Wegener's granulomatosis: a bimodal pattern. Rheumatology, 2011, 50, 697-702.	0.9	69
6	Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 1470-1479.	2.9	56
7	Healthâ€Related Quality of Life in an Inception Cohort of Children With Juvenile Idiopathic Arthritis: A Longitudinal Analysis. Arthritis Care and Research, 2018, 70, 134-144.	1.5	50
8	The importance of considering monogenic causes of autoimmunity: A somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosus. Clinical Immunology, 2017, 175, 143-146.	1.4	49
9	Identification of Novel Adenosine Deaminase 2 Gene Variants and Varied Clinical Phenotype in Pediatric Vasculitis. Arthritis and Rheumatology, 2019, 71, 1747-1755.	2.9	41
10	Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Pediatric Rheumatology, 2017, 15, 68.	0.9	39
11	Innate Control of Tissue-Reparative Human Regulatory T Cells. Journal of Immunology, 2019, 202, 2195-2209.	0.4	35
12	Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience. Rheumatology, 2020, 59, 3727-3730.	0.9	31
13	Trajectories of pain severity in juvenile idiopathic arthritis: results from the Research in Arthritis in Canadian Children Emphasizing Outcomes cohort. Pain, 2018, 159, 57-66.	2.0	29
14	Prospective Determination of the Incidence and Risk Factors of Newâ€Onset Uveitis in Juvenile Idiopathic Arthritis: The Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort. Arthritis Care and Research, 2019, 71, 1436-1443.	1.5	26
15	Predicting Which Children with Juvenile Idiopathic Arthritis Will Not Attain Early Remission with Conventional Treatment: Results from the ReACCh-Out Cohort. Journal of Rheumatology, 2019, 46, 628-635.	1.0	24
16	Clinical practice variation and need for pediatric-specific treatment guidelines among rheumatologists caring for children with ANCA-associated vasculitis: an international clinician survey. Pediatric Rheumatology, 2017, 15, 61.	0.9	20
17	Assessing the Performance of the Birmingham Vasculitis Activity Score at Diagnosis for Children with Antineutrophil Cytoplasmic Antibody-associated Vasculitis in A Registry for Childhood Vasculitis (ARChiVe). Journal of Rheumatology, 2012, 39, 1088-1094.	1.0	19
18	Serious musculoskeletal infections in children receiving anti-tumor necrosis factor-α therapy: a case series. Clinical Rheumatology, 2010, 29, 677-681.	1.0	18

#	Article	IF	CITATIONS
19	Familial Takayasu arteritis - a pediatric case and a review of the literature. Pediatric Rheumatology, 2011, 9, 6.	0.9	15
20	Natural history and extracutaneous involvement of congenital morphea: Multicenter retrospective cohort study and literature review. Pediatric Dermatology, 2018, 35, 761-768.	0.5	15
21	Worse Quality of Life, Function, and Pain in Children With Enthesitis, Irrespective of Their Juvenile Arthritis Category. Arthritis Care and Research, 2020, 72, 441-446.	1.5	15
22	Consensus Treatment Plans for Severe Pediatric Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis Care and Research, 2022, 74, 1550-1558.	1.5	15
23	Realâ€World Effectiveness of Common Treatment Strategies for Juvenile Idiopathic Arthritis: Results From a Canadian Cohort. Arthritis Care and Research, 2020, 72, 897-906.	1.5	14
24	Clinical and associated inflammatory biomarker features predictive of short-term outcomes in non-systemic juvenile idiopathic arthritis. Rheumatology, 2020, 59, 2402-2411.	0.9	11
25	Pediatric vasculitis. Current Opinion in Rheumatology, 2015, 27, 493-499.	2.0	10
26	Associations of clinical and inflammatory biomarker clusters with juvenile idiopathic arthritis categories. Rheumatology, 2020, 59, 1066-1075.	0.9	9
27	Do Adult Disease Severity Subclassifications Predict Use of Cyclophosphamide in Children with ANCA-associated Vasculitis? An Analysis of ARChiVe Study Treatment Decisions. Journal of Rheumatology, 2012, 39, 2012-2020.	1.0	8
28	Clinical and psychosocial stress factors are associated with decline in physical activity over time in children with juvenile idiopathic arthritis. Pediatric Rheumatology, 2021, 19, 97.	0.9	8
29	Different Disease Endotypes in Phenotypically Similar Vasculitides Affecting Small-to-Medium Sized Blood Vessels. Frontiers in Immunology, 2021, 12, 638571.	2.2	7
30	Complexity in unclassified auto-inflammatory disease: a case report illustrating the potential for disease arising from the allelic burden of multiple variants. Pediatric Rheumatology, 2019, 17, 70.	0.9	6
31	Impact of the COVID-19 pandemic on juvenile idiopathic arthritis presentation and research recruitment: results from the CAPRI registry. Rheumatology, 2022, 61, SI157-SI162.	0.9	6
32	Antineutrophil Cytoplasmic Antibody Associated Vasculitis. , 2016, , 484-499.e8.		5
33	Higher concentrations of vitamin D in Canadian children with juvenile idiopathic arthritis compared to healthy controls are associated with more frequent use of vitamin D supplements and season of birth. Nutrition Research, 2021, 92, 139-149.	1.3	5
34	Severe Vocal Cord Dysfunction: An Unusual Complication of Juvenile Dermatomyositis. Journal of Rheumatology, 2013, 40, 744-745.	1.0	4
35	A13: The Research in Arthritis in Canadian Children Emphasizing Outcomes (ReACCh Out) Cohort: Prospective Determination of the Incidence of New Onset Uveitis in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, S21-S22.	2.9	3
36	The risk and nature of flares in juvenile idiopathic arthritis: results from the reACCh-Out cohort. Pediatric Rheumatology, 2014, 12, .	0.9	2

#	Article	IF	CITATIONS
37	Children with systemic autoinflammatory diseases have multiple, mixed ethnicities that reflect regional ethnic diversity. Clinical and Experimental Rheumatology, 2021, 39, 124-128.	0.4	2
38	Chylous Pericardial Effusion in Granulomatosis with Polyangiitis. Nephrology, 2014, 19, 367-368.	0.7	1
39	Therapeutic Management of Pediatric Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. Current Treatment Options in Rheumatology, 2017, 3, 207-219.	0.6	1
40	Granulomatosis with Polyangiitis in Children. , 2017, , 461-478.		1
41	Wide variation in glucocorticoid dosing in paediatric ANCA-associated vasculitis with renal disease: a paediatric vasculitis initiative study. Clinical and Experimental Rheumatology, 2022, , .	0.4	1
42	Current Approach to the Evaluation and Management of Incomplete Kawasaki Disease in the Emergency Department. Pediatric Emergency Care, 2020, 36, 537-541.	0.5	0
43	Soluble Low-density Lipoprotein Receptor-related Protein 1 in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2021, 48, 760-766.	1.0	0
44	Children with systemic autoinflammatory diseases have multiple, mixed ethnicities that reflect regional ethnic diversity. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 124-128.	0.4	0